Навициксизумаб

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

DB12634

1638338-43-8

immunoglobulin G2-kappa, anti-[Homo sapiens DLL4 (delta-like 4)] and anti-[Homo sapiens VEGFA (vascular endothelial growth factor A,VEGF-A, VEGF)], humanized and chimeric monoclonal antibody, bispecific;
gamma2 heavy chain, humanized anti-DLL4 (1-445) [humanized VH (Homo sapiens IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230- 338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)],(133-218')-disulfide with kappa light chain, chimeric (1’-218’) [chimeric V-KAPPA (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')]; gamma2 heavy chain, humanized anti-VEGFA (1-447) [humanized VH (Homo sapiens IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo sapiens IGHG2*01 (CH1(122-219), hinge (220-231), CH2 (232- 340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfide with kappa light chain, chimeric (1'''-218''') [chimeric V-KAPPA (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9] (1'''-111''') -Homo sapiens IGKC*01, Km3 (112'''-218''')]; dimer (221-223":222-224":225-227":228-230")- tetrakisdisulfide

Поделиться этой страницей